Ozlem Eren

Dr. Ozlem Eren

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2025 in Clinical Endocrinology
Verified
Journal Article
Closed access
ÜÇÜmit Çavdar
Ümit Çavdar
OEOzlem Eren
Ozlem Eren
SKSerkan KARAISLI
Serkan KARAISLI
MEMehmet Sercan Ertürk
Mehmet Sercan Ertürk
BPBarış Önder Pamuk
Barış Önder Pamuk

22 October 2025 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
OEOzlem Eren
Ozlem Eren
ÜÇÜmit Çavdar
Ümit Çavdar
ASAli Salbas
Ali Salbas
AAAslı Irmak Akdoğan
Aslı Irmak Akdoğan
KKKadir Alper Küçüker
Kadir Alper Küçüker
BPBarış Önder Pamuk
Barış Önder Pamuk
Introduction: Although the vast majority of bone tumours are benign, they are a heterogeneous group of lesions with a wide spectrum of biological properties. Osteolytic, osteoblastic, or mixed-pattern changes may be observed, reflecting the heterogeneity of the underlying pathophysiological processes. Osteolytic lesions, most commonly arising from metastatic disease, multiple myeloma, or hyperparathyroidism, are the most frequently encountered presentations in clinical practice. Case presentation: Here, we report the case of a 59-year-old woman with a 3-month history of right ankle pain, in whom radiological evaluation revealed an osteolytic talar lesion initially interpreted as a giant cell tumour (GCT) and surgically excised. During postoperative oncological evaluation, a parathyroid adenoma was detected, and the patient was referred to our endocrinology clinic. Laboratory results were consistent with primary hyperparathyroidism. Re-evaluation of the bone pathology, in light of the biochemical and radiological findings and the absence of H3F3A immunostaining, supported the diagnosis of a brown tumour (BT). Following parathyroidectomy, laboratory results normalized. Discussion: Since hypercalcemia is not typically observed in GCTs, its presence should raise suspicion for metastatic or granulomatous diseases, as well as BTs associated with hyperparathyroidism. Upon detection of hypercalcemia, parathyroid hormone (PTH) levels should be evaluated as part of the differential diagnosis. Subsequent histopathological and immunohistochemical analyses can help distinguish these entities, with H3F3A immunostaining serving as an important marker for differentiating GCTs from BTs. Conclusion: This case highlights the importance of assessing serum calcium and parathyroid hormone levels, together with relevant clinical, radiological, and histopathological findings, to establish an accurate diagnosis in patients presenting with bone lesions.

21 August 2026 in Eurasian Journal of Medicine and Oncology
Verified
Journal Article
Open access
PDF file
ÜÇÜmit Çavdar
Ümit Çavdar
OEOzlem Eren
Ozlem Eren
TTTuğçe Tekinaslan
Tuğçe Tekinaslan
AKAyşegül Kavak
Ayşegül Kavak
ÖTÖykü Tuncer
Öykü Tuncer
ATAli Yasin Tümer
Ali Yasin Tümer
Introduction: Mild autonomous cortisol secretion (MACS) is usually classified by the 1-mg overnight dexamethasone suppression test (DST). However, a single post-DST cortisol value may not fully capture the chronicity or biological relevance of cortisol autonomy. Although adrenocorticotropic hormone (ACTH) and dehydroepiandrosterone sulfate (DHEAS) reflect different but biologically linked components of hypothalamic–pituitary–adrenal (HPA) axis suppression, their combined assessment has not been sufficiently evaluated in adrenal incidentalomas. Objective: To evaluate the association between the ACTH × DHEAS product and DST-defined cortisol autonomy and to explore its potential role as an ancillary biochemical marker in adrenal incidentalomas. Methods: This retrospective study included 157 patients classified as having MACS or a nonfunctioning adrenal adenoma based on post-DST cortisol levels. Patients with overt endocrine syndromes, malignant or rare adrenal lesions, and ARMC5-positive disease were excluded. Correlation analyses, sex-adjusted multivariable logistic regression, exploratory receiver operating characteristic analyses, and a DeLong test were performed. Results: MACS was present in 79 patients (50.3%). Patients with MACS had larger tumors, higher basal and post-DST cortisol, and lower ACTH, DHEAS, and ln(ACTH × DHEAS). ln(ACTH × DHEAS) was inversely correlated with post-DST cortisol and larger tumor size. After adjustment for age, sex, basal cortisol, and larger tumor size, lower ln(ACTH × DHEAS) remained independently associated with MACS (odds ratio = 0.473, 95% CI: 0.304–0.737, p = 0.001). The corrected ln(ACTH × DHEAS) showed moderate discrimination (area under the curve = 0.693) but did not significantly outperform −DHEAS alone. Conclusion: ln(ACTH × DHEAS) may serve as a practical ancillary marker of chronic HPA-axis suppression, particularly in borderline or discordant cases. It should not replace DST or DHEAS alone, and prospective outcome-based validation is required before clinical implementation.

Verified
Journal Article
Open access
PDF file
ÜÇÜmit Çavdar
Ümit Çavdar
MDMustafa Duman
Mustafa Duman
OEOzlem Eren
Ozlem Eren
MEMehmet Sercan Ertürk
Mehmet Sercan Ertürk
SKSerkan KARAISLI
Serkan KARAISLI
MHMehmet Haciyanli
Mehmet Haciyanli
Background: Given the limited and conflicting evidence regarding both the role of bisphosphonate (BP) use and the risk factors for postoperative hypocalcemia, as well as ongoing clinical hesitation toward preoperative BP use due to concerns about the occurrence of hypocalcemia, we aimed to investigate their association in patients with primary hyperparathyroidism (PHPT). Materials and Methods: A total of 73 patients undergoing parathyroidectomy were included, with 22 in the BP-positive (zoledronate) group and 51 in the BP-negative group. In BP-treated patients, biochemical values obtained after zoledronate infusion but before surgery were used as the preoperative baseline for perioperative comparisons, whereas pre-infusion calcium values were used only to characterize the clinical indication for treatment. Factors associated with postoperative hypocalcemia were evaluated using hypocalcemia as a dichotomous outcome. Results: Postoperative hypocalcemia was more frequent in BP-treated patients (27.3% vs. 3.9%, p = 0.008). However, in multivariable analysis including alkaline phosphatase (ALP), the association between BP use and hypocalcemia was attenuated and no longer statistically significant (OR 4.81, 95% CI 0.74–31.30; p = 0.100). ALP was independently associated with hypocalcemia (OR 1.016, 95% CI 1.001–1.031; p = 0.040). Additionally, hypocalcemia was associated with a shorter infusion-to-surgery interval (median 10 vs. 72 days, p = 0.0045) among BP-treated patients. Conclusions: Although hypocalcemia was more frequent among patients receiving preoperative zoledronate, this association was attenuated after adjustment for alkaline phosphatase and may reflect underlying disease severity. Alkaline phosphatase was independently associated with postoperative hypocalcemia, supporting the role of increased bone turnover. Given the limited number of events, an independent effect of zoledronate cannot be excluded, and treatment timing may warrant further investigation.

3 August 2026 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
BSBasak Ozgen Saydam
Basak Ozgen Saydam
ISILGIN YILDIRIM SIMSIR
ILGIN YILDIRIM SIMSIR
BYBerna Demir Yuksel
Berna Demir Yuksel
CACanan Altay
Canan Altay
NYNusret Yilmaz
Nusret Yilmaz
BABaris Akinci
Baris Akinci